P&G to copromote Novartis’ Enablex
Executive Summary
Procter & Gamble Pharmaceuticals will copromote Novartis' overactive bladder treatment Enablex (darifenacin), companies announce July 6. Partnership covers promotion and further development of Enablex extended-release tablets for treatment of OAB in the U.S. Agreement provides P&G and Novartis option to "collaborate in the over-the-counter commercialization should both parties decide to pursue that opportunity"...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.